Fig. 2From: Three-year outcomes for women newly initiated on lifelong antiretroviral therapy during pregnancy – Malawi option B+Proportion of women with suppressed viral load (VL < 1000 copies/mL) and undetectable viral load (VL < 40 copies/mL) over the study periodBack to article page